The safety and efficacy of transcranial direct current stimulation as add-on therapy to fluoxetine in obsessive-compulsive disorder: a randomized, double-blind, sham-controlled, clinical trial

Table 2 Clinical measures

	tDCS (n = 28)				Control (n = 30)				ANOVA (time)	ANOVA (time*group)	ANOVA (group)
	Baseline	S12	S24	M1	Baseline	S12	S24	M1	ANOVA (time)	ANOVA (time*group)	ANOVA (group)
Y-BOCS total	29.8 ± 6.6	25.0 ± 8.2	21.7 ± 9.5	22.9 ± 10.0	28.1 ± 5.7	24.8 ± 7.1	22.4 ± 8.9	21.9 ± 10.3	F_(1.85) = 30.83; P < 0.001	F_(1.85) = 0.86; P = 0.420	F_(1.00) = 0.07; P = 0.799
Y-BOCS obsession	15.2 ± 3.7	14.1 ± 3.5	11.1 ± 4.6	11.5 ± 5.0	14.1 ± 3.5	12.3 ± 4.4	11.1 ± 4.5	11.3 ± 5.4	F_(2.23) = 25.01; P < 0.001	F_(1.85) = 0.68; P = 0.523	F_(1.00) = 0.10; P = 0.748
Y-BOCS compulsion	14.3 ± 3.7	12.5 ± 4.8	11.7 ± 8.7	11.4 ± 5.3	14.0 ± 3.1	12.5 ± 3.7	11.3 ± 5.0	10.6 ± 5.5	F_(2.06) = 10.81; P < 0.001	F_(2.06) = 0.147; P = 0.869	F_(1.00) = 0.10; P = 0.748

Y-BOCS Yale–Brown Obsessive and Compulsive Scale; S12 session 12; S24 session 24; M1 1 month after the last session

ISSN: 1471-244X